Does preoperative dapagliflozin improve perioperative main pulmonary artery diameter in patients undergoing mitral valve replacement?
Preoperative dapagliflozin is associated with a smaller and more stable main pulmonary artery diameter in patients undergoing mitral valve replacement, potentially via direct vascular protective mechanisms.
Objective: To investigate the effect of preoperative use of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin on the perioperative main pulmonary artery (MPA) diameter in patients undergoing mitral valve replacement (MVR). Methods: = 157). The baseline characteristics, perioperative echocardiographic parameters, and percentage changes in serological markers were compared between the two groups. Results: = 0.035). However, there were no significant differences in the percentage changes in pulmonary artery systolic pressure (PASP), left ventricular ejection fraction (LVEF), right ventricular function (TAPSE), right ventricular basal diameter (RVBD), or N-terminal pro-B-type natriuretic peptide (NT-proBNP). Conclusion: In patients undergoing mitral valve replacement, perioperative application of dapagliflozin was independently associated with a more stable and smaller main pulmonary artery diameter. This structural benefit was dissociated from changes in estimated pulmonary artery systolic pressure, suggesting that dapagliflozin may exert positive effects on the pulmonary artery via non-pressure-dependent direct vascular protective mechanisms.
Wang et al. (Thu,) studied this question.